Answers are grounded in this paper and cite their sources.
Objective: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have a favorable impact on the kidney function in patients with heart failure (HF), while there is no clear evidence of what factors predict this effect. The aim of the study was to identify plausible predictors for kidney function outcome among patients with HF and investigate their association with SGLT2i. Design and method: We prospectively enrolled 480 patients with type 2 diabetes mellitus (T2DM) treated with diet and metformin and concomitant chronic HF and followed them for 52 weeks. We determined kidney outcome as a composite event that includes >40% reduced estimated glomerular filtration rate from baseline, newly diagnosed end-stage CKD or kidney replacement therapy. The relevant medical information and measurement of the biomarkers were collected at baseline and at the end of the study. Results: The composite kidney outcome was detected in 88 (18.3%) patients of the entire population. All patients received guideline-recommended optimal therapy, which was adjusted to phenotype/severity of HF, cardiovascular risk and comorbidity profiles, and fasting glycaemia. Levels of irisin, adropin and apelin significantly increased in patients without clinical endpoint, whereas in those with composite endpoint the biomarker levels exhibited a decrease with borderline statistical significance (Figure 1). Multivariate logistic regression revealed that use of SGLT2i (OR=0.92 p=0.048), baseline serum levels of irisin <4.50 ng/ml (OR=1.51, p=0.001) and adropin <2.10 ng/ml (OR=1.15, p=0.001) along with and a <15% increase in the levels of these biomarkers (OR=1.60, p=0.001)and <6% (OR=1.21, p=0.001), respectively, remained an independent predictor for composite kidney endpoint. We established that irisin <4.5 ng/ml and <15% increase in irisin serum levels added more valuable predictive information than the reference variable. However, the combination of irisin <4.5 ng/ml at baseline and <15% increase in irisin serum levels (area under curve = 0.91, 95% confident interval = 0.87-0.95) improved the discriminative value of each biomarker alone. Conclusions: We suggest that low levels of irisin and its inadequate increase during administration of SGLT2i are promising predictors for unfavorable kidney outcome among patients with T2DM and concomitant HF
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: